Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

No adequate supply? Semaglutide (GLP-1) weight-loss drug Wegovy, made by pharmaceutical company Novo Nordisk. (Photo: James ...

a result Metsera said was as good or better than the approved or similar GLP-1 compounds already on the market. Also worth ...

DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global ...

This includes production for the four planned DehydraTECH formulation Study arms and clinical repackaging of the commercially available Rybelsus® comparator tablets for the Study control arm as ...

“While GLP-1-based therapies have revolutionized patient care for obesity ... nausea remain two holy grails in this field,” ...

After Novo Nordisk and Eli Lilly transformed the market for obesity ... Metsera is looking to both improve on that class of ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

GLP-1 agonists – of which Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide) are the most ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...